Academic journal article Research-Technology Management

See Modest Increase in U.S. R&D Spending

Academic journal article Research-Technology Management

See Modest Increase in U.S. R&D Spending

Article excerpt

Once again, Schonfeld & Associates, Inc. is forecasting growth in R&D spending by U.S. firms in the coming calendar year, although this time the operative word is "modest."

The 33rd and latest edition of the Libertyville, Illinois consulting firm's annual R&D Ratios and Budgets expects the pharmaceutical industry to again be the biggest R&D investor, with the drug companies increasing their 2010 budgets by more than 10% to spend $110 billion. Last year's forecast called for the drug companies to increase their budgets 9.9% to $105 billion.

Schonfeld expects Eli Lilly will be the top spender in 2010 at $11.6 billion followed by Roche, Johnson & Johnson, Pfizer, Novartis, Sanofi-Aventis, Astrazeneca, Merck, and Schering-Plough, each projected to spend over $5 billion. Much of this investment is spurred by new discoveries and attempts to protect expiring patents, Schonfeld says. Electromedical apparatus makers, led by Medtronic, will spend $5.3 billion, a boost of 9.6%.

Automotive companies are forecast to add nearly $60 billion to this investment pool, an increase of 4.4%.

The major software companies will spend $33 billion on R&D in 2010, an increase of over 10%. Microsoft continues to lead, with a budget of $9.7 billion, an increase of 7.6%. Oracle, SAP and Electronic Arts will also invest over $1 billion in 2010. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.